OPTIMISE Lung SABR
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is a phase II multi-centre, randomised study independently evaluating five fraction Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR) and three fraction IG-SABR for patients with a peripherally located T1-T2 and selected T3 and T4 lung tumours, or a peripherally located single pulmonary oligometastatic lesion.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Spodziewana długość życia ponad 6 miesięcy
- •Potwierdzona diagnoza pierwotnego raka płuca (niedrobnokomórkowego) lub pojedynczego przerzutu do płuca
- •Guz umiejscowiony na obrzeżu płuca, nienadający się do operacji lub pacjent odmawia operacji
- •Dobra ogólna kondycja zdolna do tolerowania leczenia
- •Kobiety w wieku rozrodczym muszą być niepłodne, nie karmiące piersią i stosować antykoncepcję podczas leczenia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
St Luke's Radiation Oncology Network (SLRON) at St Luke's Hospital and St James's Hospital
Dublin, Ireland
Trial contact
Cancer Trials Ireland RCSI House, 121 St Stephen's Green, Dublin 2
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.